Preface

US Renal Data System 2017 Annual Data Report: Epidemiology of Kidney Disease in the United States

Suggested Citation: Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2017 Annual Data Report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2018;71(3)(suppl 1):Svii,S1-S672.

Support: Funding for the USRDS Coordinating Center and preparation of the USRDS Annual Data Report is provided under contract to University of Michigan Kidney Epidemiology and Cost Center (HHSN 27620140001C).

Financial Disclosure: Dr Bragg-Gresham is a consultant with the Medical Education Institute involving quality-of-life performance measures. Dr Herman is chair of the Data Monitoring Committee for both Merck and Lexicon Pharmaceuticals and also a consultant for Janssen Scientific Affairs, LLC. Dr Kalantar-Zadeh has financial interests with the following entities: Abbott, Abbvie, Alexion, Amgen, Astra-Zeneca, Aveo, Chugai, DaVita, Fresenius, Genentech, Haymarket Media, Hospira, Kabi, Keryx, Novartis, Pfizer, Relypsa, Resverlogix, Sandoz, Sanofi, Shire, Vifor, UpToDate, ZS-Pharma. Dr Kovesdy is a consultant for Abbott, Abbvie, Amgen, Bayer, Keryx and Sanofi-Aventis. Dr Molnar is a consultant for Merck and Abbvie. Dr Morgenstern is a consultant at Arbor Research Collaborative for Health. Dr Obi received honoraria for lectures from Ono Pharmaceutical and Chugai Pharmaceutical. Dr O’Hare received speaker fees from Dialysis Clinic Inc., Fresenius Medical Care, the University of Alabama at Birmingham, and the University of Pennsylvania; she also received honoraria from UpToDate. Dr Sim has investigator-initiated research grants from Keryx Pharmaceuticals, Malinckrodt Pharmaceuticals, and Ostuka Pharmaceuticals. The other authors declare that they have no relevant financial interests.